Securities code: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) securities abbreviation: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) Announcement No.: 2022014 Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266)
Announcement on the share increase plan of the actual controller, some directors, senior managers and core managers of the company
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) (hereinafter referred to as “the company”), the actual controller, some directors, senior managers and core managers, based on their confidence in the future development of the company and their recognition of the long-term investment value of the company, intend to, Increase the company’s shares by means allowed by the trading system of Shanghai Stock Exchange (including but not limited to centralized bidding and block trading), with a total increase of no less than 18.8 million yuan and no more than 23.7 million yuan.
There may be risks that the shareholding increase plan cannot be implemented due to changes in securities market conditions and policy factors. If the above-mentioned risk situations occur during the implementation of the shareholding increase plan, the company will timely perform the obligation of information disclosure.
1、 Basic information of the increased holding subject
(I) name of the increased shareholding entity: Mr. Zelin Sheng, the controlling shareholder, one of the actual controllers, chairman and general manager of the company, Ms. Lu Huiping, one of the actual controllers, director and executive deputy general manager, Mr. Jisheng Wu, director and deputy general manager, Mr. LV Binhua, deputy general manager, Mr. Junli Zhang, deputy general manager, Ms. Gao Qingping, deputy general manager and Secretary of the board of directors, Mr. Huang Gang, deputy general manager and financial director, Mr. Ding Wei, vice president of marketing, and Mr. Peng Jian, executive vice president of drug development and registration strategy.
(II) as of the disclosure date of this announcement, the shareholding of the above-mentioned increase subjects is as follows:
Sequence name shareholding quantity shareholding proportion No
1. Zelin Sheng directly holds 49636620 shares of the company and indirectly holds 110010 shares of the company through Kunshan 20.73% (Sheng Zelin) and shanjing’ao
Directly holding 12565440 shares of the company through Ning
2 Lu Huiping, Bo zeao and Ningbo Jingchen indirectly hold 5.85% of 1478233 shares of the company
3. Jisheng Wu indirectly holds 0.39% (Wu Jisheng) of 943888 shares of the company through Kunshan Jingao
4. LV Binhua indirectly holds 1.68% of the company’s 4025885 shares through Kunshan Jingao and Ningbo zeao
Zhang jun5
6 Gao Qingping indirectly holds 2.20% of 5286775 shares of the company through Ningbo zeao, Kunshan Jingao and Ningbo Jingchen
7. Huang Gang indirectly holds 0.37% of 897567 shares of the company through Ningbo zeao
8 Ding Wei indirectly holds 0.51% of 1214349 shares of the company through Ningbo Jingchen
9. Peng Jian does not hold shares-
Note: 1. Kunshan Jingao refers to “Kunshan Jingao pharmaceutical technology partnership (limited partnership)”, Ningbo Jingchen refers to “Ningbo Jingchen investment partnership (limited partnership)”, and Ningbo zeao refers to “Ningbo zeao equity investment management partnership (limited partnership)”. 2. As of the disclosure date of this announcement, Mr. Zelin Sheng and Ms. Lu Huiping, the actual controllers of the company, controlled 843213600 shares of the issuer directly or indirectly, accounting for 35.13% of the total share capital of the issuer, including the shares of Kunshan Jingao, Ningbo Jingchen and Ningbo zeao.
(III) in the 12 months before the disclosure of this announcement, the above-mentioned increase subjects have not disclosed the increase plan.
2、 Main contents of the shareholding increase plan
(I) purpose of the proposed increase in shares
Based on the confidence in the future development of the company and the recognition of the long-term investment value of the company, the increase subject plans to increase the shares of the company in order to boost the confidence of investors, safeguard the interests of small and medium-sized investors and support the sustainable and stable development of the company in the future.
(II) amount and type of shares to be increased this time
The total amount of shares to be increased by the increase subject this time shall not be less than RMB 18.8 million and not more than RMB 23.7 million. The type of additional shares is the company’s A-share common stock. Of which:
Mr. Zelin Sheng plans to increase his holdings by no less than RMB 10 million and no more than RMB 11 million;
Ms. Lu Huiping plans to increase her holdings by no less than RMB 2 million and no more than RMB 2.5 million; Mr. Jisheng Wu (Wu Jisheng) plans to increase his holdings by no less than RMB 1 million and no more than RMB 1.5 million;
Mr. LV Binhua plans to increase his holdings by no less than RMB 1 million and no more than RMB 1.5 million; Mr. Junli Zhang (Zhang Junli) intends to increase his holdings by no less than RMB 1 million and no more than RMB 1.5 million;
Ms. Gao Qingping plans to increase her holdings by no less than 1 million yuan and no more than 1.5 million yuan; Mr. Huang Gang plans to increase his holdings by no less than RMB 800000 and no more than RMB 1.2 million;
Mr. Ding Wei plans to increase his holdings by no less than RMB 1 million and no more than RMB 1.5 million;
Mr. Peng Jian plans to increase his holdings by no less than RMB 1 million and no more than RMB 1.5 million.
(III) price of shares to be increased this time
The plan does not set the price range of the shares to be increased, and the increase subject will choose the opportunity to increase the shares according to the fluctuation of the company’s stock price and the overall trend of the capital market.
(IV) implementation period of the share increase plan
The share increase plan of the company is planned to be completed within 6 months from March 3, 2022. During the implementation of the increase plan, if the trading of the company’s shares is suspended, the increase period can be postponed, and the company will perform the obligation of information disclosure in time.
(V) capital arrangement for the proposed increase of shares
The increase subject plans to increase the shares of the company through its own funds or self raised funds.
(VI) the way to increase shares this time
Increase the shares of the company by means allowed by the trading system of Shanghai Stock Exchange (including but not limited to centralized bidding and block trading).
3、 Uncertainty risk of the implementation of the shareholding increase plan
There may be risks that the shareholding increase plan cannot be implemented due to changes in securities market conditions and policy factors. If the above-mentioned risk situations occur during the implementation of the shareholding increase plan, the company will timely perform the obligation of information disclosure.
4、 Other instructions
(I) the implementation of this share increase plan will not lead to the distribution of shares of the company not meeting the listing conditions, the change of the controlling shareholders and actual controllers of the company, and the impact on the corporate governance structure and sustainable operation.
(II) in the process of implementing the share increase plan, the increase subject will abide by the relevant provisions of China Securities Regulatory Commission and Shanghai Stock Exchange on changes in equity of listed companies and sensitive periods of stock trading. (III) the company will continue to pay attention to the progress of this shareholding increase plan and fulfill the obligation of information disclosure in a timely manner in accordance with the provisions of relevant laws, administrative regulations, departmental rules and normative documents, such as the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of the acquisition of listed companies, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange and so on.
It is hereby announced.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) board of directors March 3, 2022
